MLX 0871
Alternative Names: MLX-0871Latest Information Update: 26 Jun 2024
At a glance
- Originator Biolexis Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 21 Jun 2024 Biolexis Therapeutics plans a phase-I trial for Type 2 diabetes mellitus and obesity (PO) in Q2 2025
- 17 Apr 2024 Preclinical trials in Obesity in USA (PO) prior to April 2024 (Biolexis Therapeutics pipeline, April 2024)
- 17 Apr 2024 Preclinical trials in Type 2 diabetes mellitus in USA (PO) prior to April 2024 (Biolexis Therapeutics pipeline, April 2024)